Showing results (251-260 of 301) with videos related to
Sort By:
Pageof 31
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2006
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trialFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.Oncotarget|June 26, 2018
Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CTFanny Foubert, Sébastien Gouard, Catherine Saï-Maurel, et al.Cancer Research|September 26, 2014
Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancerSusanne Lütje, Mark Rijpkema, David M Goldenberg, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 28, 2016
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human TrialCaroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2012
A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancersRobert M Sharkey, Catharina M van Rij, Habibe Karacay, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 25, 2017
α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer XenograftsSandra Heskamp, Reinier Hernandez, Janneke D M Molkenboer-Kuenen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 22, 2004
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugatesGary L Griffiths, Chien-Hsing Chang, William J McBride, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II resultsFranck Morschhauser, John P Leonard, Luis Fayad, et al.Frontiers in Medicine|June 20, 2019
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic ApproachesCaroline Bodet-Milin, Clément Bailly, Yann Touchefeu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphomaErnst J Postema, John M M Raemaekers, Wim J G Oyen, et al.Pageof 31